The Decentralized Clinical Trials (DCT) Working Party publishes quality-based principles and risk assessment considerations for patient-focused decentralization of clinical trials.
The Risk-Based Quality Management (RBQM) Working Group releases new report showcasing changes in the RBQM landscape.
Click here for ACRO’s latest statements on the COVID-19 pandemic.
Read about ACRO’s initiatives, COVID-19 efforts, and more.
Take a look at how our members are innovating in top focus areas.
Half of all clinical trials occur in the US. ACRO works with US legislators and regulators to ensure a positive regulatory environment that supports high-quality, safe and ethical clinical research. More »
ACRO engages with European regulators, connecting its members with critical stakeholders. We support the clinical research industry and provide CRO expertise. More »
ACRO’s CRO Forum is a formal mechanism to enable clinical research organizations to interact with TransCelerate BioPharma Inc. on a range of issues that impact the industry. More »
In Europe and the US, ACRO gathers government leaders and key stakeholders to inform, educate and promote the unique contributions of clinical research and technology companies. More »
We help create a predictable, enabling business environment. ACRO’s proactive agenda is focused on policy outcomes that advance specific operational interests of ACRO members. More »
ACRO’s Global Data Protection & Privacy Committee advances issues of data privacy, protection and security, and how the industry interprets policies and prepares for upcoming legislation. More »
Get ACRO’s free quarterly newsletter to stay informed about our work and the industry.
Risk-based monitoring (RBM) is a powerful tool for efficiently ensuring patient safety and data integrity in a clinical trial, enhancing overall trial…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Steve…
Ironically, the Pfizer-BioNTech Covid-19 vaccine program did not take “Operation Warp Speed” funding. Even more ironic is the fact that Pfizer got…
It was a familiar scenario: A rare disease area of oncology. A new drug candidate. A desire to assess efficacy as safely and quickly as possible, so that if successful, a new therapy could get approved and change lives. But this desire could have been tempered by reality: the trial was going to be challenging and slow…
For the clinical research industry, technological tools improve trial continuity, and generate data that helps power more robust monitoring of safety and quality. They can also be a natural fit for patients. IQVIA also sees study participants liking the direct shipment of medicines, telehealth interactions and at-home visits. In the COVID era and beyond, designing more trials with these kinds of technology-enabled strategies is going to help more people by lowering barriers to participation, and speeding the development of new medicines.
Diverse technology solutions, like patient telehealth visits, accessing electronic medical records (EMRs) or remote source data verification, can generate vast amounts of data. As the clinical research industry evolves towards its next “new normal” with a higher baseline level of remote monitoring, IQVIA is considering the implications of increasing data access. Are we ready?
We help create a global regulatory and business environment
where ACRO members succeed
